Sign in
Taking peoplePhase 2

Continued PGN-EDODM1 treatment for myotonic dystrophy type 1

Checks lasting safety of PGN-EDODM1 for myotonic dystrophy type 1.

Key facts

Who runs it
PepGen Inc
Where
Canada3 sites in 1 countryChoose a country to see its sites
Trial code
Registry title
An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE)
Status
Recruiting
Phase
Phase 2
People taking part
48 people, planned
Started
23 Dec 2025
Expected to end
Jan 2029
Type of study
Interventional
Treatments tested
  • PGN-EDODM1
Record updated
30 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people with myotonic dystrophy type 1 (DM1) who have completed an earlier study with PGN-EDODM1. It studies the long-term safety of PGN-EDODM1.

Sex
All sexes can join.
Disease stage
Myotonic dystrophy type 1 (DM1).
Earlier treatment
People must have completed a prior study with PGN-EDODM1. People cannot join if they used another experimental drug, device or product within 30 days or 5 half-lives before study entry, whichever is longer.

Main reasons for not taking part

  • Abnormal lab test results at screening that the study doctor considers important
  • Use of another experimental drug, device or product (other than PGN-EDODM1) within 30 days or 5 half-lives before study entry, whichever is longer

The registry criteria, word for word

Show all 3 criteriaShow less

Who can take part

  • Participant has completed a prior study with PGN-EDODM1

Who cannot take part

  • Use of an investigational drug (other than PGN-EDODM1), device, or product, within 30 days or 5 half-lives of the study drug (whichever is longer) prior to study entry
  • Abnormal laboratory tests at screening considered clinically significant by the Investigator

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of this study is to learn about the long-term safety and tolerability of PGN-EDODM1 in participants with myotonic dystrophy type 1 (DM1) who have completed a prior study with PGN-EDODM1.

The group in the trial

  • PGN-EDODM1Treatment being tested

    Participants will receive doses of PGN-EDODM1 once every 4 weeks (Q4W)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
An Open-Label Extension Study Evaluating Safety and Pharmacokinetics in Participants With Myotonic Dystrophy Type 1 (FREEDOM-OLE)
Plain-language title
Continued PGN-EDODM1 treatment for myotonic dystrophy type 1Generated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
30 March 2026